ES2191857T3 - 7alfa-(epsilon-aminoalquil)-estratrienos, procedimiento para su preparacion, formulaciones farmaceuticas que contienen estos 7alfa-(epsilon-aminoalquil)-estratrienos asi como su utilizacion para la preparacion de medicamentos. - Google Patents
7alfa-(epsilon-aminoalquil)-estratrienos, procedimiento para su preparacion, formulaciones farmaceuticas que contienen estos 7alfa-(epsilon-aminoalquil)-estratrienos asi como su utilizacion para la preparacion de medicamentos.Info
- Publication number
- ES2191857T3 ES2191857T3 ES97943814T ES97943814T ES2191857T3 ES 2191857 T3 ES2191857 T3 ES 2191857T3 ES 97943814 T ES97943814 T ES 97943814T ES 97943814 T ES97943814 T ES 97943814T ES 2191857 T3 ES2191857 T3 ES 2191857T3
- Authority
- ES
- Spain
- Prior art keywords
- hydrogen atom
- group
- atom
- radical
- sup
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 abstract 12
- -1 HYDROCARBON RADICAL Chemical class 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract 3
- 229940046836 anti-estrogen Drugs 0.000 abstract 3
- 239000000328 estrogen antagonist Substances 0.000 abstract 3
- 229930195733 hydrocarbon Natural products 0.000 abstract 3
- 150000003254 radicals Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 abstract 1
- 241000243251 Hydra Species 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 229940099990 ogen Drugs 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 238000009256 replacement therapy Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000003258 trimethylene group Chemical class [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCION DESCRIBE NUEVOS 7 AL - ( XI AMINOALQUIL) - ESTRATRIENOS SUSTITUIDOS DE FORMULA GENERAL (I), EN DONDE LAS CADENAS LATERALES SK REPRESENTAN UN RADICAL DE FORMULA PARCIAL (II), EN DONDE M ES 4, 5 O 6, N ES 0, 1 O 2, X ES 0, 1 O 2, A ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO DE C SUB,1-5 , B Y D SON CADA UNO UN ATOMO DE HIDROGENO, O A Y B JUNTOS FORMAN UN GRUPO ALQUILENO (CH 2 ) P - SIENDO P = 2, 3, 4, O 5 Y D UN ATOMO DE HIDROGENO, O A Y D FORMAN JUNTOS UN GRUPO ALQUILENO (CH 2 ) Q - , SIENDO Q = 2, 3 O 4, Y B ES UN ATOMO DE HIDROGENO, Y E ES UN RADICAL ETILICO INSUSTITUIDO O FLUORADO DE 1 A 5 VECES, O EL SUSTITUYENTE TERMINAL (CH2 ) 3 - E EN LA CADENA TERMINAL ESTA SUSTITUIDO POR UN RADICAL ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO, QUE ESTA UNIDO DE MANERA DIRECTA O MEDIANTE UN GRUPO MONO -, DI - O TRIMETILENO AL ATOMO DE AZUFRE, R 3 ES UN ATOMO DE HIDROGENO, UN RADICAL DE HIDROCARBURO CON HASTA 8 ATOMOS DE CARBONO O UN RADICAL DE FORMULA PARCIAL R 3'' - C(O) -, SIENDO R SUP,3'' UN ATOMO DE HIDROGENO O UN RADICAL DE HIDROCARBURO CON HASTA 8 ATOMOS DE CARBONO, O UN RADICAL FENILO, R 11 ES UN ATOMO DE HIDROGENO, UN ATOMO DE HALOGENO O UN GRUPO OXIDADO DE NITRO - O - NO 2 , R 14 , R 15 AL , R 15 BE , R 16 AL Y R 16 BE SON CADA UNO UN ATOMO DE HIDR OGENO, O R 14 Y R 15 AL SON UN ENLACE ADICIONAL O UN PUENTE DE METILENO, O R 15 BE ES UN GRUPO METILO, Y R SUP,15 AL ES UN ATOMO DE HIDROGENO, O R 15 AL Y R 1 5 BE SON CADA UNO UN GRUPO METILO, O R 15 BE O R 16BE FORMAN JUNTOS UN PUENTE DE METILENO, O R 16 AL O R 16 BE SON UN ATOMO DE HALOGENO, O R 16 AL Y R SUP,16 BE FORMAN JUNTOS UN GRUPO DE METILURO, Y EL RESTO DE LOS SUSTITUYENTES R 14 , R 15 AL , R 15 BE , R 16 AL Y R 16 BE SON CADA UNO UN ATOMO DE HIDROGENO, R S UP,17 ES UN ATOMO DE HIDROGENO EN POSICION AL O EN POSICION BE , UN GRUPO ALQUILO DE C 1-5 , UN GRUPO ALQUENILO DE C SUB,2-5 , O UN GRUPO ALQUINILO DE C 2-5 , UN GRUPO DE TRIF LUOROMETILO, Y R 17'''' ES UN ATOMO DE HIDROGENO, O UN RADICAL DE FORMULAPARCIAL R 17'''''' - C(O) -, EN DONDE R 1 7'''''' ES UN ATOMO DE HIDROGENO O UN RADICAL DE HIDROCARBURO CON HASTA 7 U 8 ATOMOS DE CARBONO O SI R 17'' SE ENCUENTRA EN LA POSICION AL , R 17'' JUNTO CON R 14 FORMA UN PUENTE DE ETANO, CON LA CONDICION DE QUE SI A Y B FORMAN JUNTOS (CH 2 ) P- , O A Y D FORMAN JUNTOS - (CH 2 ) Q -, AL MENOS UNO DE LOS SUSTITUYENTES R 11 , R 14 , R SUP,15 AL , R 15 BE Y R 16 BE NO ES UN ATOMO DE H IDROGENO; ASI COMO SUS SALES FISIOLOGICAMENTE ACEPTABLES DE ADICION CON ACIDOS ORGANICOS E INORGANICOS. LOS NUEVOS COMPUESTOS REPRESENTAN COMPUESTOS DE UNA ELEVADA ACTIVIDAD ANTIESTROGENO. EN LOS COMPUESTOS DE LA INVENCION SE TRATA POR UNA PARTE DE ANTIESTROGENOS PUROS, O POR OTRA PARTE DE ANTIESTROGENOS CON UN EFECTO PARCIAL ESTROGENICO. A CAUSA DE ESTE ESPECTRO DE ACCION LOS NUEVOS COMPUESTOS SON MUY APROPIADOS PARA LA PREPARACION DE MEDICAMENTOS PARA LA TERAPIA TUMORAL Y PARA LA TERAPIA HORMONAL DE SUSTITUCION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19635525A DE19635525A1 (de) | 1996-08-20 | 1996-08-20 | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2191857T3 true ES2191857T3 (es) | 2003-09-16 |
Family
ID=7804367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97943814T Expired - Lifetime ES2191857T3 (es) | 1996-08-20 | 1997-08-20 | 7alfa-(epsilon-aminoalquil)-estratrienos, procedimiento para su preparacion, formulaciones farmaceuticas que contienen estos 7alfa-(epsilon-aminoalquil)-estratrienos asi como su utilizacion para la preparacion de medicamentos. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0920441B1 (es) |
| JP (1) | JP2001503024A (es) |
| KR (1) | KR20000068261A (es) |
| CN (1) | CN1231670A (es) |
| AR (1) | AR009278A1 (es) |
| AT (1) | ATE231882T1 (es) |
| AU (1) | AU728843B2 (es) |
| BG (1) | BG62972B1 (es) |
| BR (1) | BR9711328A (es) |
| CA (1) | CA2263708A1 (es) |
| CZ (1) | CZ57999A3 (es) |
| DE (2) | DE19635525A1 (es) |
| DK (1) | DK0920441T3 (es) |
| EA (1) | EA001577B1 (es) |
| EE (1) | EE04021B1 (es) |
| ES (1) | ES2191857T3 (es) |
| HU (1) | HUP9903106A3 (es) |
| IL (1) | IL128601A (es) |
| IS (1) | IS4976A (es) |
| NO (1) | NO315655B1 (es) |
| NZ (1) | NZ334277A (es) |
| PL (1) | PL186309B1 (es) |
| PT (1) | PT920441E (es) |
| SK (1) | SK18899A3 (es) |
| TR (1) | TR199900432T2 (es) |
| TW (1) | TW552267B (es) |
| UA (1) | UA50792C2 (es) |
| WO (1) | WO1998007740A1 (es) |
| ZA (1) | ZA977482B (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR015500A1 (es) * | 1997-12-23 | 2001-05-02 | Schering Ag | 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS. |
| US6548491B2 (en) | 1997-12-24 | 2003-04-15 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6503896B1 (en) | 1997-12-24 | 2003-01-07 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| DE19807791A1 (de) | 1998-02-19 | 1999-08-26 | Schering Ag | Kombinationspräparat aus Östrogen und Antiöstrogen |
| DE19833786A1 (de) * | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE19842123C1 (de) * | 1998-09-05 | 2000-07-13 | Schering Ag | 11beta-Fluor-7alpha-(14,14,15,15,15-pentafluor-6- methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)- trien-3,17beta-diol als kristallines Ansolvat |
| DE19906159A1 (de) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
| WO2001012622A1 (en) * | 1999-08-18 | 2001-02-22 | Schering Aktiengesellschaft | Piperidine and pyrrolidine derivatives displaying neuronal activity |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| DE10019171A1 (de) * | 2000-04-07 | 2001-10-18 | Schering Ag | Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe |
| AU2006202187B2 (en) * | 2001-11-27 | 2008-11-06 | Bayer Schering Pharma Aktiengesellschaft | 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations |
| DE10159217A1 (de) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| EP1771462B1 (en) | 2004-07-27 | 2010-09-29 | Sicor Inc. | A process for the preparation of 7-alpha-alkylated 19-norsteroids |
| CN101312944B (zh) | 2005-11-22 | 2013-03-06 | 住友化学株式会社 | 有机硫化合物及其作为节肢动物杀灭剂的应用 |
| DE102007049630A1 (de) | 2007-10-11 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| DE102007023614A1 (de) | 2007-05-21 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| TW200904329A (en) | 2007-05-18 | 2009-02-01 | Sumitomo Chemical Co | Organic sulfur compound and its use for controlling harmful arthropod |
| JP5298631B2 (ja) | 2007-05-18 | 2013-09-25 | 住友化学株式会社 | 有機硫黄化合物及びその有害節足動物防除用途 |
| JP2009001551A (ja) | 2007-05-18 | 2009-01-08 | Sumitomo Chemical Co Ltd | 有機硫黄化合物及びその有害節足動物防除用途 |
| DE102007032800A1 (de) | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| SG185311A1 (en) | 2007-10-16 | 2012-11-29 | Repros Therapeutics Inc | Trans-clomiphene for metabolic syndrome |
| DE102007058747A1 (de) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| EP2070941A1 (en) | 2007-12-14 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Stereoselective synthesis of selective estrogen receptor down-regulators |
| EP2070909A1 (de) | 2007-12-15 | 2009-06-17 | Bayer Schering Pharma AG | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| DE102008057230A1 (de) | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
| JP5212350B2 (ja) | 2008-12-24 | 2013-06-19 | 住友化学株式会社 | 含ハロゲン有機硫黄化合物およびその用途 |
| EP2258375A1 (de) | 2009-06-04 | 2010-12-08 | Bayer Schering Pharma Aktiengesellschaft | 17B-alkyl-17alpha-oxy-estratriene |
| DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| KR20160088947A (ko) | 2010-06-16 | 2016-07-26 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
| DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE102011004899A1 (de) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| FI2753632T3 (fi) | 2011-09-08 | 2023-08-02 | Sage Therapeutics Inc | Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä |
| DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US20150031656A1 (en) | 2012-02-29 | 2015-01-29 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| US20160296534A1 (en) | 2013-04-11 | 2016-10-13 | Bayer Pharma Aktiengesellschaft | Progesterone receptor antagonist dosage form |
| CN104936971B (zh) * | 2013-04-18 | 2017-10-13 | 西安力邦医药科技有限责任公司 | 具有抗癌活性的7‑α‑[9‑(4，4，5，5，5‑五氟戊基亚硫酰基)壬基]‑雌甾‑1，3，5(10)‑三烯‑3，17β‑二醇的酯类衍生物及其制备方法 |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| FI3828194T3 (fi) | 2015-07-06 | 2025-07-17 | Sage Therapeutics Inc | Oxysteroleita ja menetelmiä niiden käyttämiseksi |
| EP3373967B9 (en) | 2015-11-10 | 2023-10-04 | Paracrine Therapeutics AB | Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen |
| US20190330259A1 (en) | 2016-04-01 | 2019-10-31 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| LT3481846T (lt) | 2016-07-07 | 2021-08-25 | Sage Therapeutics, Inc. | 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles |
| JP7149266B2 (ja) | 2016-09-30 | 2022-10-06 | セージ セラピューティクス， インコーポレイテッド | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
| IL293231B2 (en) | 2016-10-18 | 2025-10-01 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| CN115505019B (zh) * | 2022-11-07 | 2024-01-26 | 南宁师范大学 | 7-酰胺取代雌甾类化合物及其制备方法和应用 |
| CN116041412A (zh) * | 2023-01-13 | 2023-05-02 | 香港中文大学（深圳） | 氟维司群衍生物及其制备方法、应用和治疗乳腺癌的药物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
| DE3925507A1 (de) * | 1989-07-28 | 1991-01-31 | Schering Ag | 14,17(alpha)-etheno- und ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln |
| DE4218743C2 (de) * | 1992-06-04 | 2001-10-25 | Schering Ag | Verfahren zur Herstellung C(7)-substituierter Estra-1,3,5(10)-triene sowie neue Ausgangsprodukte für dieses Verfahren |
-
1996
- 1996-08-20 DE DE19635525A patent/DE19635525A1/de not_active Withdrawn
-
1997
- 1997-08-20 TR TR1999/00432T patent/TR199900432T2/xx unknown
- 1997-08-20 CA CA002263708A patent/CA2263708A1/en not_active Abandoned
- 1997-08-20 CZ CZ99579A patent/CZ57999A3/cs unknown
- 1997-08-20 EP EP97943814A patent/EP0920441B1/de not_active Expired - Lifetime
- 1997-08-20 DE DE59709239T patent/DE59709239D1/de not_active Expired - Fee Related
- 1997-08-20 EE EEP199900075A patent/EE04021B1/xx not_active IP Right Cessation
- 1997-08-20 AR ARP970103779A patent/AR009278A1/es not_active Application Discontinuation
- 1997-08-20 NZ NZ334277A patent/NZ334277A/xx unknown
- 1997-08-20 HU HU9903106A patent/HUP9903106A3/hu unknown
- 1997-08-20 DK DK97943814T patent/DK0920441T3/da active
- 1997-08-20 AT AT97943814T patent/ATE231882T1/de not_active IP Right Cessation
- 1997-08-20 AU AU45520/97A patent/AU728843B2/en not_active Ceased
- 1997-08-20 ES ES97943814T patent/ES2191857T3/es not_active Expired - Lifetime
- 1997-08-20 PT PT97943814T patent/PT920441E/pt unknown
- 1997-08-20 EA EA199900210A patent/EA001577B1/ru not_active IP Right Cessation
- 1997-08-20 UA UA99031552A patent/UA50792C2/uk unknown
- 1997-08-20 ZA ZA9707482A patent/ZA977482B/xx unknown
- 1997-08-20 KR KR1019997001396A patent/KR20000068261A/ko not_active Ceased
- 1997-08-20 JP JP10510412A patent/JP2001503024A/ja not_active Ceased
- 1997-08-20 CN CN97198245A patent/CN1231670A/zh active Pending
- 1997-08-20 IL IL12860197A patent/IL128601A/xx not_active IP Right Cessation
- 1997-08-20 SK SK188-99A patent/SK18899A3/sk unknown
- 1997-08-20 WO PCT/EP1997/004517 patent/WO1998007740A1/de not_active Ceased
- 1997-08-20 TW TW086111927A patent/TW552267B/zh active
- 1997-08-20 PL PL97331863A patent/PL186309B1/pl not_active IP Right Cessation
- 1997-08-20 BR BR9711328A patent/BR9711328A/pt unknown
-
1999
- 1999-02-11 IS IS4976A patent/IS4976A/is unknown
- 1999-02-16 BG BG103185A patent/BG62972B1/bg unknown
- 1999-02-19 NO NO19990793A patent/NO315655B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| CR7698A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| AR026633A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| UY26086A1 (es) | Procedimientos e intermedios para preparar compuestos anticancerosos | |
| ES2181803T3 (es) | Acidos 4-biarilbutiricos o 5-biarilpentanoicos sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz. | |
| ES2164758T3 (es) | Derivados de morfolina sustituidos y su uso como agentes terapeuticos. | |
| PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| HN1999000149A (es) | Derivados de 4,4-biarilpiperidina | |
| DOP2003000566A (es) | Cicloalcanindoles con sustitución con fluor, composiciones que contienen estos compuestos y metodos de preparación para un medicamento | |
| ES2138323T3 (es) | Derivados de benzoilo herbicidas. | |
| CR8482A (es) | Nuevos derivados de quinolina | |
| ES2158314T3 (es) | Oximas, hidrazonas y olefinas sustituidas como antagonistas de la neuroquinina. | |
| ES2192588T3 (es) | 4-(arilaminometilen)-2,4-dihidro-pirazol-3-onas. | |
| CY1106781T1 (el) | Περιορισμενα ως προς τη διαμορφωση κυκλοποιημενα στην κυρια αλυσιδα αναλογα σωματοστατινης | |
| ES2185094T3 (es) | Combinacion sinergica de agentes ignifugos para las resinas sinteticas. | |
| PE20041040A1 (es) | Compuestos derivados de amidas como inhibidores de 11-beta-hidroxiesteroide-deshidroxigenasa de tipo 1 | |
| ES2151819B1 (es) | Difenilaminas noniladas. | |
| PA8576001A1 (es) | "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso". | |
| ES2180625T3 (es) | Derivados de camptotecina solubles en agua, proceso para su preparacion y su uso como agentes antitumorales. | |
| AR013153A1 (es) | Derivados de 2-arildihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados, y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n. | |
| PA8589601A1 (es) | Derivados de indazol como antagonistas del crf | |
| ES2180041T3 (es) | Derivados de 5-oxido de piridazino(4,5-b)quinoleina, su preparacion y su uso como antagonistas de glicina. | |
| ES2192722T3 (es) | Productos intermedios para la obtencion de oximeteres. | |
| AR037100A1 (es) | Compuesto de pirimidina de anillo fusionado alquinilado, proceso de preparacion, compuestos intermedios, composicion farmaceutica y usi para preparacion de un producto medicinal | |
| ES2026669T3 (es) | Procedimiento para la preparacion y el uso terapeutico de los beta-d-fenil tioxilosidos. |